Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.

Employees

26,921

Sector

Pharmaceuticals

Calendar

13/02/2025 - Q3 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
10/12/24	974.20 ₹	-0.84%	664,912
09/12/24	982.45 ₹	-1.27%	1,191,543
06/12/24	995.10 ₹	+1.75%	749,783
05/12/24	978.00 ₹	+0.79%	697,437
04/12/24	970.35 ₹	-1.20%	1,385,360

Delayed Quote NSE India S.E., December 10, 2024 at 11:49 am

More quotes

Income Statement and Estimates

income-statement-evolution-chart ZYDUS-LIFESCIENCES-LIMITE

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

974.20INR

Average target price

1,083.36INR

Spread / Average Target

+11.21%

Consensus

Profit revisions

estimates-change-chart ZYDUS-LIFESCIENCES-LIMITE

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart ZYDUS-LIFESCIENCES-LIMITE

Company calendar

Market Closed - NSE India S.E. Other stock markets 11:49:38 10/12/2024 GMT			5-day change	1st Jan Change
974.20 ^INR	-0.84%		-0.04%	+41.35%

11-29	Zydus Lifesciences Limited Receives Demand Order-In-Original from Assistant Commissioner, Division Dehradun, Sector-7, Uttarakhand	CI
11-14	Nomura Adjusts Zydus Lifesciences' Price Target to INR1,030 From INR1,020, Keeps at Neutral	MT

Capitalization	980B 11.55B 10.99B 10.19B 9.06B 16.36B 18.13B 127B 46.83B 403B 43.37B 42.43B 1,757B	P/E ratio 2025 *	22.1x	P/E ratio 2026 *	21.3x
Enterprise value	955B 11.26B 10.72B 9.93B 8.83B 15.94B 17.67B 124B 45.65B 392B 42.27B 41.36B 1,712B	EV / Sales 2025 *	4.2x	EV / Sales 2026 *	3.78x
Free-Float	-	Yield 2025 *	0.61%	Yield 2026 *	0.66%

Zydus Lifesciences Limited Receives Demand Order-In-Original from Assistant Commissioner, Division Dehradun, Sector-7, Uttarakhand	11-29	CI
Nomura Adjusts Zydus Lifesciences' Price Target to INR1,030 From INR1,020, Keeps at Neutral	11-14	MT
Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,380 From INR1,450, Keeps at Buy	11-13	MT
Zydus Lifesciences Posts Gains in Fiscal Q2 Consolidated Net Profit	11-13	MT
Zydus Lifesciences Limited, Q2 2025 Earnings Call, Nov 12, 2024	11-12
India's Zydus Life posts Q2 profit rise on steady US demand	11-12	RE
Zydus Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	11-12	CI
Zydus Lifesciences Limited Receives in Principle Acceptability from World Health Organization for Zyvac Tcv	10-23	CI
Zydus Lifesciences Limited Receives Final Approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 Mg	10-17	CI
Zydus Lifesciences to Start Phase 2 Trials of Desidustat for Sickle Cell Disease	10-14	MT
Zydus Lifesciences Limited and ICMR Initiate A Phase 2 Proof-Of-Concept Trial of Desidustat in Patients with Sickle Cell Disease	10-14	CI
Zydus Lifesciences Limited Receives Final Approval from USFDA for Paliperidone Extended-Release Tablets	10-10	CI
Zydus Lifesciences Gets Tentative Nod from US FDA for Enzalutamide Tablets	10-02	MT

Nomura Adjusts Zydus Lifesciences' Price Target to INR1,030 From INR1,020, Keeps at Neutral	11-14	MT
Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,380 From INR1,450, Keeps at Buy	11-13	MT
Jefferies Upgrades Zydus Lifesciences to Buy From Hold, Adjusts Price Target to INR1,450 From INR1,210	08-28	MT
Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,210 From INR1,070, Keeps at Hold	08-12	MT
Nomura Downgrades Zydus Lifesciences to Neutral From Buy, Adjusts Price Target to INR1,020 From INR988	05-21	MT

Zydus Lifesciences Limited Share Price

Equities

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Valuation: Zydus Lifesciences Limited

Chart: Zydus Lifesciences Limited

Latest news: Zydus Lifesciences Limited

Last Transcript: Zydus Lifesciences Limited

Analysts' recommendations: Zydus Lifesciences Limited

Press Releases: Zydus Lifesciences Limited

News in other languages: Zydus Lifesciences Limited

Quotes and Performance

Course Extremes

Managers and Directors: Zydus Lifesciences Limited

ETFs: Zydus Lifesciences Limited

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Zydus receives final approval from USFDA for Scopolamine Transdermal System 1 mg/3 days	09-02	AQ
Zynext Ventures Invests in neuro42, A Company Developing Portable MRI Systems for Neuroimaging and Interventions	08-15	AQ
Zynext Ventures, the VC arm of Zydus Lifesciences, Announces Investment in Promaxo: Pioneering Point-of-Care Medical Imaging and Interventions with Next Generation MRI Systems	06-18	AQ
Sentynl Therapeutics Announces Global Acquisition of Zokinvy for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals	05-06	AQ
Zydus launches Mirabegron Extended-Release Tablets in the US	04-22	BU

EXCLUSIVA-Eli Lilly podría lanzar un fármaco contra la obesidad en India el próximo año: presidente ejecutivo	02-28
Biocon : Farmacéuticas indias se vuelven locales para terminar con dependencia de China	23/02/21
Des laboratoires indiens intéressés par les génériques de Sanofi	11/01/18

1 day	-0.84%
1 week	-0.04%
Current month	+0.85%
1 month	+0.40%
3 months	-11.77%
6 months	-7.73%
Current year	+41.35%

Director	Title	Age	Since
Sharvil Pankajbhai Patel CEO	Chief Executive Officer	45	26/11/2009
Nitin Dalsukhrai Parekh DFI	Director of Finance/CFO	-	-
Dhaval Narendra Soni CMP	Compliance Officer	-	06/02/2019

Manager	Title	Age	Since
Sharvil Pankajbhai Patel BRD	Director/Board Member	45	31/03/2007
Mukesh Mangalbhai Patel BRD	Director/Board Member	69	31/07/1997
Pankaj Ramanbhai Patel CHM	Chairman	71	04/10/2011

Name	Weight	AuM	1st Jan change	Investor Rating
WISDOMTREE INDIA EX-STATE-OWNED ENTERPRISES FUND ETF - USD	0.22%	6 M€	+6.07%	-
LEADERSHARES EQUITY SKEW ETF - USD	0.01%	92 M€	+16.36%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
ZYDUS LIFESCIENCES LIMITED	-0.84%	-0.04%	+52.56%	+110.68%	11.65B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+0.18%	+0.08%	+46.46%	+138.23%	51.08B
OTSUKA HOLDINGS CO., LTD.	+0.16%	-0.58%	+57.59%	+112.56%	31.33B
SANDOZ GROUP AG	-0.18%	-2.72%	+39.45%	-	18.98B
CIPLA LIMITED	-0.94%	-3.48%	+19.37%	+62.68%	13.98B
THE MEDICINES COMPANY	-.--%	+0.14%	-	-	6.79B
STADA ARZNEIMITTEL	-.--%	-1.95%	-	-	5.73B
ONO PHARMACEUTICAL CO., LTD.	+0.56%	-0.72%	-32.54%	-37.92%	5.32B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-0.03%	-1.59%	+4.45%	+20.22%	5.23B
GLENMARK PHARMACEUTICALS LIMITED	+1.88%	-0.32%	+93.81%	+203.82%	5.04B
Average	+0.15%	-0.93%	+35.14%	+87.18%	15.51B
Weighted average by Cap.	+0.08%	-0.80%	+43.00%	+110.68%

	2025 *	2026 *
Net sales	227B 2.68B 2.55B 2.36B 2.1B 3.79B 4.2B 29.41B 10.86B 93.31B 10.05B 9.84B 407B	243B 2.86B 2.73B 2.53B 2.25B 4.06B 4.49B 31.45B 11.61B 99.78B 10.75B 10.52B 435B
Net income	44.51B 524M 499M 463M 411M 743M 823M 5.76B 2.13B 18.28B 1.97B 1.93B 79.75B	46.25B 545M 519M 481M 428M 772M 855M 5.99B 2.21B 18.99B 2.05B 2B 82.88B
Net Debt	-24.82B -292M -278M -258M -229M -414M -459M -3.21B -1.19B -10.19B -1.1B -1.07B -44.47B	-61.59B -726M -691M -640M -569M -1.03B -1.14B -7.97B -2.94B -25.29B -2.72B -2.67B -110B